SCHEMBL9837697

SCHEMBL9837697

CCNc1c(N)cnc2ccccc12

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 1/20 0.42
PKM P14618 1/20 0.42
KMT2A Q03164 1/20 0.42
NCF1 P14598 1/20 0.42
KDM4E B2RXH2 2/20 0.41
GAA P10253 1/20 0.41
MAPT P10636 1/20 0.41
HSD17B10 Q99714 1/20 0.41
LRRK2 Q5S007 1/20 0.40
HRH3 Q9Y5N1 2/20 0.39
KDM1A O60341 1/20 0.39
GPR3 P46089 1/20 0.39
TLR7 Q9NYK1 1/20 0.39
ELANE P08246 1/20 0.39
APP P05067 1/20 0.39
CYP1A1 P04798 1/20 0.38
CYP1A2 P05177 1/20 0.38
PI4KA P42356 1/20 0.38
PI4K2B Q8TCG2 1/20 0.38
PI4K2A Q9BTU6 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL10731384 0.98 MEN1 (0.41) MEN1PKMKMT2ANCF1KDM4E
SCHEMBL18843434 0.87 APP (0.50) MEN1PKMKMT2AKDM4EGAA
SCHEMBL5118839 0.84 S1PR2 (0.49) MEN1PKMKMT2AHRH3ELANE
SCHEMBL13645285 0.83 NCF1 (0.42) MEN1PKMKMT2ANCF1KDM4E
SCHEMBL12665011 0.83 POLB (0.44) MEN1PKMKMT2ANCF1KDM4E
SCHEMBL31197374 0.83 ACP1 (0.47) MEN1PKMKMT2ANCF1KDM4E
SCHEMBL31197376 0.83 ACP1 (0.47) MEN1PKMKMT2ANCF1KDM4E
SCHEMBL4725461 0.83 ACP1 (0.47) MEN1PKMKMT2ANCF1KDM4E
SCHEMBL14345376 0.83 ATM (0.39) MEN1PKMKMT2ANCF1KDM4E
SCHEMBL13963101 0.83 ACHE (0.49) MEN1PKMKMT2ANCF1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130225555-A1 Imidazoquinolines with Immuno-Modulating Properties DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2013-08-29 US disclosed
US-8436178-B2 Imidazoquinolines with immuno-modulating properties ASTRAZENECA AB (SE) 2013-05-07 US disclosed
US-20110136801-A1 Novel Compounds DAINIPPON SUMITOMO PHARMA CO. LTD. (JP) 2011-06-09 US disclosed
US-20100280001-A1 IMIDAZOQUINOLINES WITH IMMUNO-MODULATING PROPERTIES SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) 2010-11-04 US disclosed
US-7598382-B2 Aryl substituted imidazoquinolines COLEY PHARMACEUTICAL GROUP, INC. (US) 2009-10-06 US disclosed
US-20070259881-A1 Substituted Imidazo Ring Systems and Methods COLEY PHARMACEUTICAL GROUP, INC. 2007-11-08 US disclosed
EP-0223420-B1 CONDENSED IMIDAZOPYRIDINE DERIVATIVES SHIONOGI & CO., LTD. (JP) 1991-02-27 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100280001-A1 IMIDAZOQUINOLINES WITH IMMUNO-MODULATING PROPERTIES IFNG, FCGRT, IFNAR1 MEN1 678/4885PKM 2531/4885KMT2A 1124/4885
US-20070259881-A1 Substituted Imidazo Ring Systems and Methods IL2, IL4, IRF3 MEN1 2899/4885PKM 3364/4885KMT2A 2601/4885
US-20110136801-A1 Novel Compounds C1R, RB1, CNKSR1 MEN1 181/4885PKM 1840/4885KMT2A 3167/4885
US-20130225555-A1 Imidazoquinolines with Immuno-Modulating Properties IFNG, FCGRT, IFNAR1 MEN1 678/4885PKM 2531/4885KMT2A 1124/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.